Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors.

Piña Y, Houston SK, Murray TG, Koru-Sengul T, Decatur C, Scott WK, Nathanson L, Clarke J, Lampidis TJ.

Clin Ophthalmol. 2012;6:817-30. doi: 10.2147/OPTH.S29688. Epub 2012 May 29.

2.

Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.

Piña Y, Decatur C, Murray TG, Houston SK, Lopez-Cavalcante M, Hernandez E, Celdran M, Shah N, Feuer W, Lampidis T.

Invest Ophthalmol Vis Sci. 2012 Feb 27;53(2):996-1002. doi: 10.1167/iovs.11-8265. Print 2012 Feb.

3.

Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors.

Houston SK, Pina Y, Clarke J, Koru-Sengul T, Scott WK, Nathanson L, Schefler AC, Murray TG.

Invest Ophthalmol Vis Sci. 2011 Jul 23;52(8):5359-68. doi: 10.1167/iovs.10-6321.

4.

Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors.

Piña Y, Decatur C, Murray T, Houston S, Gologorsky D, Cavalcante M, Cavalcante L, Hernandez E, Celdran M, Feuer W, Lampidis T.

Clin Ophthalmol. 2011;5:337-43. doi: 10.2147/OPTH.S16172. Epub 2011 Mar 7.

5.

Bilateral orbital vasculature alterations after systemic chemotherapy and external beam radiation therapy treatment of advanced retinoblastoma: implications for intraarterial chemotherapy management.

Boutrid H, Wolfe SQ, Murray TG, Pina Y, Moftakhar R, Fernandes CE, Reichbach J, Aziz-Sultan MA.

Retin Cases Brief Rep. 2011 Spring;5(2):124-7. doi: 10.1097/ICB.0b013e3181c5999c.

PMID:
25389879
6.

Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors.

Houston SK, Piña Y, Murray TG, Boutrid H, Cebulla C, Schefler AC, Shi W, Celdran M, Feuer W, Merchan J, Lampidis TJ.

Clin Ophthalmol. 2011 Jan 27;5:129-37. doi: 10.2147/OPTH.S15179.

7.

Antiangiogenic activity of 2-deoxy-D-glucose.

Merchan JR, Kovács K, Railsback JW, Kurtoglu M, Jing Y, Piña Y, Gao N, Murray TG, Lehrman MA, Lampidis TJ.

PLoS One. 2010 Oct 27;5(10):e13699. doi: 10.1371/journal.pone.0013699.

8.

Ophthalmic vasculature alterations following systemic chemotherapy and periocular Carboplatin treatment of advanced retinoblastoma.

Piña Y, Boutrid H, Murray TG, Wolfe SQ, Schefler AC, Houston SK, Moftakhar R, Fernandes CE, Reichbach J, Aziz HA, Markoe AM, Aziz-Sultan MA.

J Pediatr Ophthalmol Strabismus. 2010 Sep 22;47 Online:e1-5. doi: 10.3928/01913913-20100920-04.

PMID:
20886809
9.

Clinical imaging and high-resolution ultrasonography in melanocytoma management.

Gologorsky D, Schefler AC, Ehlies FJ, Raskauskas PA, Pina Y, Williams BK, Murray TG.

Clin Ophthalmol. 2010 Aug 9;4:855-9.

10.

Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma.

Piña Y, Houston SK, Murray TG, Boutrid H, Celdran M, Feuer W, Shi W, Hernandez E, Lampidis TJ.

Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6149-56. doi: 10.1167/iovs.09-5033. Epub 2010 Aug 11.

11.

Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis.

Cavalcante LL, Cavalcante ML, Murray TG, Vigoda MM, Piña Y, Decatur CL, Davis RP, Olmos LC, Schefler AC, Parrott MB, Alliman KJ, Flynn HW, Moshfeghi AA.

Clin Ophthalmol. 2010 May 25;4:519-24.

12.

Supraselective injection of intraarterial melphalan as the primary treatment for late presentation unilateral multifocal stage Vb retinoblastoma.

Aziz HA, Boutrid H, Murray TG, Berrocal A, Wolfe SQ, Pina Y, Dorfman M, Moftakhar R, Fernandes CE, Reichbach J, Aziz-Sultan MA.

Retina. 2010 Apr;30(4 Suppl):S63-5. doi: 10.1097/IAE.0b013e3181cbda0f.

PMID:
20224464
13.

Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate.

Bajenaru ML, Piña Y, Murray TG, Cebulla CM, Feuer W, Jockovich ME, Marin Castaño ME.

Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2860-4. doi: 10.1167/iovs.09-4500. Epub 2010 Jan 27.

14.

Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype.

Piña Y, Boutrid H, Murray TG, Jager MJ, Cebulla CM, Schefler A, Ly LV, Alegret A, Celdran M, Feuer W, Jockovich ME.

Invest Ophthalmol Vis Sci. 2010 May;51(5):2671-7. doi: 10.1167/iovs.09-4255. Epub 2010 Jan 6.

15.

Increased hypoxia following vessel targeting in a murine model of retinoblastoma.

Boutrid H, Piña Y, Cebulla CM, Feuer WJ, Lampidis TJ, Jockovich ME, Murray TG.

Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5537-43. doi: 10.1167/iovs.09-3702. Epub 2009 Jul 2.

PMID:
19578014
16.

Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature.

Piña Y, Cebulla CM, Murray TG, Alegret A, Dubovy SR, Boutrid H, Feuer W, Mutapcic L, Jockovich ME.

Ophthalmic Res. 2009;41(3):160-9. doi: 10.1159/000209670. Epub 2009 Mar 26.

17.

Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment.

Piña Y, Boutrid H, Schefler A, Dubovy S, Feuer W, Jockovich ME, Murray TG.

Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1020-4. doi: 10.1167/iovs.08-2654. Epub 2008 Oct 24.

PMID:
18952925
18.

Basic fibroblast growth factor impact on retinoblastoma progression and survival.

Cebulla CM, Jockovich ME, Piña Y, Boutrid H, Alegret A, Kulak A, Hackam AS, Bhattacharya SK, Feuer WJ, Murray TG.

Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5215-21. doi: 10.1167/iovs.07-1668. Epub 2008 Jul 9.

19.

Heterogeneous tumor vasculature in retinoblastoma: implications for vessel targeting therapy.

Jockovich ME, Piña Y, Alegret A, Cebulla C, Feuer W, Murray TG.

Retina. 2008 Mar;28(3 Suppl):S81-6. doi: 10.1097/IAE.0b013e318150d6f0. Erratum in: Retina. 2009 Jan;29(1):127.

PMID:
18317352
20.

Targeting hypoxia, a novel treatment for advanced retinoblastoma.

Boutrid H, Jockovich ME, Murray TG, Piña Y, Feuer WJ, Lampidis TJ, Cebulla CM.

Invest Ophthalmol Vis Sci. 2008 Jul;49(7):2799-805. doi: 10.1167/iovs.08-1751. Epub 2008 Mar 7.

PMID:
18326690

Supplemental Content

Loading ...
Support Center